Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Therapy in Critically Ill Patients With Ventilator-associated Pneumonia
Key facts
- Who runs it
- Centre Hospitalier Universitaire de Nīmes
- Where
- France2 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 124 people, planned
- Started
- 27 Mar 2026
- Expected to end
- 27 Apr 2028
- Type of study
- Interventional, 2 groupsOne group gets no study treatment, for comparison.
- Treatments tested
- strategy combining respiratory mPCR and algorithm-based therapy developed using local epidemiology
- Record updated
- 13 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Adults (≥18 years) with VAP (mechanical ventilation and hospitalization ≥ 48 hours) and deep respiratory sample by mini BAL < 12 hours. The diagnosis of pneumonia includes two clinical criteria among fever (≥38.3°C), purulent sputum or aspiration, hyperleukocytosis (>12,000 WBC/mm³) or leukopenia (<4,000 WBC/mm³), hypoxemia, auscultatory signs in the affected area, and a newly-appeared parenchymal infiltrate
- Patient receiving initial probabilistic antibiotic therapy for VAP suspicion
- Informed consent or emergency procedure
- Patient affiliated with or beneficiary of a health insurance plan; Non inclusion Criteria:
- Pregnancy
- Congenital immunodeficiency
- HIV infection with the lymphocyte CD4 count below 200/mm3 or unknown in the last year
- Acute hematologic malignancy
- Neutropenia (<1 leucocyte/mL or < 0.5 neutrophil/mL)
- Immunosuppressive drugs within the previous 30 days, including anti-cancer - Chemotherapy and anti-rejection drugs for organ/bone marrow transplant
- Corticosteroids ≥ 20 mg/d of prednisone equivalent for more than 14 days
- Known allergy to beta-lactams
- Moribund patient or death expected from underlying disease during the current admission
- Patient deprived of liberty or under legal protection measure
- Participation in another interventional trial
Who cannot take part
- mPCR non available
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Assess the impact of a strategy combining respiratory mPCR and algorithm-based therapy developed using local epidemiology on the early optimization of initial antibiotic therapy for ventilator-associated pneumonia (VAP) (intervention), compared to a conventional strategy (control).
Read full original descriptionShow less
A bicentric, parallel-group, randomized controlled trial. The primary assessment criterion is the proportion of early optimized antibiotic therapy within 24 hours of respiratory sampling.
The 2 groups in the trial
- combined use of mPCR and algorithm-based therapyTreatment being tested
strategy combining respiratory mPCR on a deep respiratory sample obtained by mini bronchoalveolar lavage and algorithm-based therapy developed using local epidemiology
Treatment: strategy combining respiratory mPCR and algorithm-based therapy developed using local epidemiology
- Conventional strategy for antibiotic therapy at discretion of ICU physiciansNo study treatment, for comparison
The conventional strategy is based on the clinician's choice in accordance with best practice recommendations, without the combined use of respiratory mPCR and algorithm-based therapy.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Combined Use of a Respiratory Multiplex PCR and Algorithm-based Therapy to Improve Early Optimization of Antibiotic Therapy in Critically Ill Patients With Ventilator-associated Pneumonia : a Bicentric, Parallel-group, Randomized Controlled Trial.
- Record updated
- 13 October 2026